Immuno-gene therapy approaches for cancer: from in vitro studies to clinical trials. Front Biosci 2008 May 01;13:3202-14
Date
05/30/2008Pubmed ID
18508428DOI
10.2741/2921Scopus ID
2-s2.0-42649109659 (requires institutional sign-in at Scopus site) 21 CitationsAbstract
Immunotherapy against cancer basically aims at either broadly stimulating the immune system or at engineering an immune response against a targeted tumor associated antigen (TAA). In this review, we focus on the translation of immuno-gene therapy strategies into clinical trials for various cancers. Rather than being an exhaustive compendium of the literature, the focus of this article is to underline how anti-cancer immunotherapy strategies have evolved recently. Previously, studies have used different vectors to either express immuno-stimulatory molecules or a targeted TAA. Investigators are now directing efforts to both target a TAA and to stimulate the immune system by direct or viral administration of cytokines or co-stimulatory molecules. Some groups have also tried to combine genetic immunotherapy with chemotherapy, and results have been encouraging. This novel concept might open new perspectives for the treatment of patients with advanced-stage cancer.
Author List
Loisel-Meyer S, Foley R, Medin JAAuthor
Jeffrey A. Medin PhD Professor in the Pediatrics department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Cancer VaccinesClinical Trials as Topic
Dendritic Cells
Dependovirus
Genetic Therapy
Humans
Immunotherapy
Neoplasms
Retroviridae
T-Lymphocytes
Vaccines, DNA
Viruses
